Immune Activity Equipment & Supplies In Belarus
105 equipment items found
Manufactured by:Beijing Enhalor International Tech Co., Ltd. based inHaidian District, CHINA
Halor Tid is an antimicrobial peptide designed to fight against a range of Gram-negative ...
Manufactured by:Emergent BioSolutions Inc. based inGaithersburg, MARYLAND (USA)
VAXCHORA is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1 in adults 18 through 64 years of age traveling to cholera-affected ...
Manufactured by:multimmune GmbH based inMunich, GERMANY
ENKASTIM is based on the activation of immune cells called natural killer (NK) cells that are major players in the body's first line of defense, also called innate immunity. The immune effector cells are activated ex vivo (outside the body; ENKASTIM-ev) or in vivo (inside the body; ...
Manufactured by:Virbac Animal Health India Pvt. Ltd. based inMumbai, INDIA
Virbac's RABIGEN Mono is a single-strain, killed vaccine indicated for the prevention of Rabies. RECOMMENDED FOR Active immunization of dogs and cats against ...
Manufactured by:Virbac Animal Health India Pvt. Ltd. based inMumbai, INDIA
FELIGEN CRP is a modified live vaccine for cats and kittens to protect against the deadly core disease caused by feline Calicivirus, Rhinotracheitis virus and Panleucopenia ...
Manufactured by:Integrated DNA Technologies, Inc. based inCoralville, IOWA (USA)
The Alt-R CRISPR-Cas9 System includes all of the reagents needed for successful genome editing based on the natural S. pyogenes CRISPR-Cas9 system. Discover what makes the Alt-R CRISPR-Cas9 system best in ...
Manufactured by:Newgen Biotech(Ningbo) Co.,Ltd based inXiangshan County, CHINA
Product formula: Hydatid powder (addition amount 87.2%, containing β-glucan), Luo Han Guo powder, yam powder, hawthorn powder, Bifidobacterium lactis, R. rhamnosus, yeast β-glucan, oat-β- Glucan. Product specifications: 5g * 20 / box. How to eat: Take it directly or take it with water below 37 ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
We have developed an EBOV glycoprotein vaccine candidate (Ebola GP vaccine) expressed in insect cells, using our core recombinant baculovirus technology. In 5 separate studies, carried out in collaboration with the National Institute of Allergy and Infectious Diseases, active immunization with the Ebola GP vaccine was shown to be highly immunogenic and efficacious in preventing lethal disease in ...
by:Onegene Biotechnology based inSuwon, SOUTH KOREA
OGB23501 is a first-in-class tri-specific tumor microenvironment (TME) immune activator, which simultaneously targets PD-1, CTLA-4, and VEGF. We aim to develop it as a potential backbone therapy for melanoma, NSCLC, HCC, and renal ...
Manufactured by:Capricor Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Our core therapeutic technology (CAP-1002) is based on cardiosphere-derived cells, or CDCs, a cardiac-derived cell therapy that was first identified in the academic laboratory of Capricor’s scientific founder, Dr. Eduardo Marbán. Since the initial publication in 2007, CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to ...
Manufactured by:Aptevo Therapeutics based inSeattle, WASHINGTON (USA)
ADAPTIR-FLEX technology extends advantages of ADAPTIR technology to create protein therapeutics with varied specificity and valency and potentially new modes of ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
By combining bi-valency with bi-specificity in the tetravalent format, the dual checkpoint molecule utilizes avidity and bi-specificity to improve anti-cancer immune cell function. The specificity enhancement both synergistically enhance and expand the breadth of immune cell activity that is diminished in cancer patients (SEBA). The spatio-temporal control of bi-specificity ensure that ...
by:Hookipa Pharma Inc. based inVienna, AUSTRIA
Our scientific platform includes two distinct approaches to arenavirus-based therapies: replicating and non-replicating. Our replicating technology is designed to create a stronger immune response that we believe is more appropriate for use in oncology. Our non-replicating technology is designed to evoke a potent immune response for prophylactic use against infectious disease. ...
Manufactured by:BriaCell Therapeutics Corp. based inWest Vancouver, BRITISH COLUMBIA (CANADA)
Bria-IMT™ (developed from a breast cancer cell line) is a patented (USPTO) immunotherapy approach that directly stimulates the body’s own cancer fighting cells to attack and destroy breast cancer tumors. ...
Manufactured by:Virometix AG based inSchlieren, SWITZERLAND
Effective antigen delivery and a strong and durable response is the basis for successful cancer vaccines. The SVLP approach, with its modular and flexible design, the inherent adjuvant properties and other immune system activators, lends itself to the development of particle-based vaccines against cancer: SVLPs displaying cancer antigens are optimally presented to the immune system and trigger ...
Manufactured by:Aptevo Therapeutics based inSeattle, WASHINGTON (USA)
Demonstrated ability to produce monospecific and bispecific drug candidates; Leverages IgG1 Fc to form homodimeric bispecific molecules; IgG1-derived Fc can be mutated to ablate effector functions antibody-dependent cellcytotoxicity (ADCC) and complementdependent cytotoxicity (CDC), while maintaining original stability and half-life (confirmed by cell binding, cell function, SPRbased measurements ...
by:Fusix Biotech based inMünchen, GERMANY
The FUSIX Technology relies on a fusion-based oncolytic virus platform. Below you can see FUB101 in action. In this timelapse video FUB101 is killing a monolayer of cancer cells (HCC) within 48 hours through a fusogenic mechanism of action. The FUSIX technology is based on a hybrid virus construct combining all the advantages of both parental platforms while minimizing risks factors. This ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
SL-701 is an immunotherapy designed to direct the immune system to attack targets present on certain malignancies including brain cancer. SL-701 comprises 3 short synthetic peptides that correspond to epitopes of targets including IL-13Rα2, EphA2, and survivin; 2 of these synthetic peptides (IL-13Rα2 and survivin) are mutant and believed to enhance immune activity. A multicenter Phase ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
Guidance and Navigation Control (GNC) molecules are multi-specific cell engager proteins. GNC in the oncology therapeutics class bind to cancer cells and to immune cells and stimulate the immune cell cancer killing activity. By design, each GNC molecule is multi-function. In the process of killing, the GNC is designed to educate and empower the T cells to be more effective at killing ...
Manufactured by:OncoVITA based inParis, FRANCE
Oncovita’s MeasovirTM proprietary platform relies on a DNA plasmid vector that expresses a modified measles Schwarz virus antigenome able to generate recombinant viruses by using a clonal reverse genetics system. This versatile plug-and-play platform allows producing new viruses expressing very large amounts of additional genetic ...